Early response monitoring of neoadjuvant chemotherapy using [ 18 F]FDG PET can predict the clinical outcome of extremity osteosarcoma

Background To propose a personalized therapeutic approach in osteosarcoma treatment, we assessed whether sequential [18F]FDG PET/CT (PET/CT) could predict the outcome of patients with osteosarcoma of the extremities after one cycle and two cycles of neoadjuvant chemotherapy.